摘要目的:比较玻璃体内注射康柏西普与注射雷珠单抗治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿的效果。方法:回顾性分析徐州市第一人民医院2017年9月至2019年8月BRVO所致黄斑水肿49例(49眼)的资料，按玻璃体内注射药物将其分为康柏西普组23例(23眼)和雷珠单抗组26例(26眼)，两组患者均接受连续3次的玻璃体腔注射，每次间隔1个月，随访期间再次出现黄斑水肿时，按需进行注射。随访6个月，比较两组视力及黄斑中心区视网膜厚度。结果:两组在注药后1、2、3及6个月的视力均较注射前提高(均 P<0.05)，两组组间差异无统计学意义( P>0.05)；两组在各时间点注药后的黄斑中心区厚度均较注射前降低(均 P<0.05)，两组组间差异无统计学意义( P>0.05)。 结论:玻璃体内注射康柏西普与雷珠单抗治疗BRVO所致黄斑水肿均有良好的效果及安全性。

abstractsObjective:To compare the efficacy of intravitreal injection of conbercept and ranibizumab in the treatment of macular edema secondary to branch retinal vein occlusion (BRVO).Methods:The data of 49 eyes of 49 cases with macular edema secondary to BRVO from Sep. 2017 to Aug. 2019 in Xuzhou First People’s Hospital were analyzed retrospectively. They were divided into conbercept group of 23 eyes and ranibizumab group of 26 eyes, based on different drug of intravitreal injection. The patients in both groups received intravitreal injection for 3 times, with an interval of 1 month. When macular edema (CMT>250μm) occurred again during the follow-up period, intravitreal injection was performed as needed. The follow-up time was 6 months. The visual acuity and the central macular thickness(CMT) were observed and compared between the two groups.Results:The visual acuity of the two groups at 1, 2, 3 and 6 months after injection were higher than that before injection (all P<0.05), and there was no significant difference between the two groups ( P>0.05). The CMT of the two groups at 1, 2, 3 and 6 months after injection were lower than that before injection (all P<0.05). There was no significant difference between the two groups ( P>0.05). Conclusion:Intravitreal injection of conbercept and ranibizumab has good efficacy and safety in the treatment of macular edema caused by BRVO.